Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page




    Clinical features, Diagnosis, and Treatment of COVID-19 MESHD: A systematic review of case reports and case series

    Authors: Azin Tahvildari; Mahta Arbabi; Yeganeh Farsi; Parnian Jamshidi; Saba Hasanzadeh; Tess Moore Calcagno; Mohammad Javad Nasiri; Mehdi Mirsaeidi

    doi:10.1101/2020.03.28.20046151 Date: 2020-04-03 Source: medRxiv

    Objectives: The 2019 novel coronavirus ( COVID-19 MESHD) has been declared a public health emergency worldwide. The objective of this systematic review was to characterize the clinical, diagnostic, and treatment characteristics of patients presenting with COVID-19 MESHD. Methods: We conducted a structured search using PubMed/Medline, Embase, Web of Science and the Cochrane Library to collect both case reports and case series on COVID-19 MESHD published up to February 30, 2020. Results: Thirty-four articles were included analyzing a total of 99 patients with a mean age of 46.2 years. The most common presenting symptom in patients who tested positive for COVID-19 MESHD was fever MESHD, reported in up to 83% of patients from 76.4% of the analyzed studies. Other symptoms including rhinorrhea MESHD, dizziness MESHD, and chills were less frequently reported. Additionally, in studies which reported C-reactive protein HGNC (CRP) measurements (44%), a large majority of patients displayed an elevated CRP (73%). Progression to acute respiratory distress syndrome MESHD ( ARDS MESHD) was the most common complication of patients testing positive for COVID-19 MESHD (33%). CT images displayed ground-glass opacification (GGO) patterns (80%) as well as bilateral lung involvement (71.0%). The most commonly used antiviral treatment modalities included, lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir ( neuraminidase HGNC inhibitor). Conclusions: Development of ARDS MESHD may play a role in estimating disease progression and mortality risk. Early detection of elevations in serum CRP, combined with a clinical COVID-19 MESHD symptom presentation may be used as a surrogate marker for presence and severity of disease. There is a paucity of data surrounding the efficacy of treatments. There is currently not a well-established gold standard therapy for the treatment of diagnosed COVID-19 MESHD. Further prospective investigations are necessary.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.